ERBB2 and neoplasm: When the mice were given trastuzumab shortly after tumor implantation, despite the original absence of HER2 overexpression in the model, tumor growth could be halted, forming the basis to postulate an adjuvant effect of trastuzumab on HER2-negative disease [31].